Literature DB >> 10768591

Epidemiologic aspects of renal cell cancer.

J K McLaughlin1, L Lipworth.   

Abstract

Renal cell cancer accounts for about 2% of cancers worldwide. It has been increasing in incidence in North America and northern Europe, but not in other areas of the world. In the United States the rate of increase has been about 3% per year, with the highest rates now seen among blacks. Survival has improved, with the 5-year relative survival rate increasing from 30% to 40% in the 1960s to between 50% and 60% in the 1990s. A large number of epidemiologic studies, particularly case-control investigations, have searched for clues to the etiology. Cigarette smoking is a causal factor in the development of renal cell cancer. Virtually every study has identified obesity or high relative weight as another major determinant, particularly among women. High blood pressure or its medications may also play a role, although the mechanism is unknown. Occupational exposures such as asbestos, coke oven emissions, gasoline, and solvents have been related to an excess risk, but no convincing evidence exists regarding these or any other occupational factor. An inverse association between risk and intake of fruits and vegetables has been seen in a number of studies and remains one of the few consistent dietary findings. A relation with coffee, alcohol, or any other beverage has not been demonstrated for renal cell cancer and is unlikely to exist. Genetic susceptibility plays a significant role in an unknown portion of cases, likely through a number of mechanisms. Future etiologic studies should focus on the mechanism by which obesity increases risk, the role of high blood pressure and its medications, and the reasons for the remarkedly rapid increase in incidence among blacks in the United States.

Entities:  

Mesh:

Year:  2000        PMID: 10768591

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  55 in total

1.  Predictive factors for response to treatment in patients with advanced renal cell carcinoma.

Authors:  Carolina Muriel López; Emilio Esteban; Aurora Astudillo; Pablo Pardo; Jose Pablo Berros; Marta Izquierdo; Guillermo Crespo; Paula J Fonseca; Miguel Sanmamed; Pablo Martínez-Camblor
Journal:  Invest New Drugs       Date:  2012-05-27       Impact factor: 3.850

2.  The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.

Authors:  Dietmar W Siemann; W D Brazelle; Juliane M Jürgensmeier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-01       Impact factor: 7.038

3.  A prospective study of one-carbon metabolism biomarkers and risk of renal cell carcinoma.

Authors:  Todd M Gibson; Stephanie J Weinstein; Susan T Mayne; Ruth M Pfeiffer; Jacob Selhub; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes; Rachael Stolzenberg-Solomon
Journal:  Cancer Causes Control       Date:  2010-04-10       Impact factor: 2.506

4.  Occupational risk factors for kidney cancer: a cohort study in Sweden.

Authors:  Jianguang Ji; Charlotta Granström; Kari Hemminki
Journal:  World J Urol       Date:  2005-11-08       Impact factor: 4.226

5.  Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.

Authors:  Chun-Xiong Zhao; Chun-Li Luo; Xiao-Hou Wu
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

6.  Polymorphisms in genes related to activation or detoxification of carcinogens might interact with smoking to increase renal cancer risk: results from The Netherlands Cohort Study on diet and cancer.

Authors:  Kim M Smits; Leo J Schouten; Boukje A C van Dijk; Kjeld van Houwelingen; Christina A Hulsbergen-van de Kaa; Lambertus A L M Kiemeney; R Alexandra Goldbohm; Egbert Oosterwijk; Piet A van den Brandt
Journal:  World J Urol       Date:  2007-11-03       Impact factor: 4.226

7.  MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients.

Authors:  Kai Doberstein; Nico Steinmeyer; Ann-Kathrin Hartmetz; Wolfgang Eberhardt; Michel Mittelbronn; Patrick N Harter; Eva Juengel; Roman Blaheta; Josef Pfeilschifter; Paul Gutwein
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

Review 8.  Lifestyle issues and genitourinary tumours.

Authors:  Frank Sommer; Theo Klotz; Bernd J Schmitz-Dräger
Journal:  World J Urol       Date:  2003-12-12       Impact factor: 4.226

9.  Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value.

Authors:  Carsten Kempkensteffen; Stefan Hinz; Frank Christoph; Hans Krause; Ahmed Magheli; Mark Schrader; Martin Schostak; Kurt Miller; Steffen Weikert
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-09       Impact factor: 4.553

10.  A phase II trial of pemetrexed in patients with metastatic renal cancer.

Authors:  R Thödtmann; T Sauter; S Weinknecht; L Weissbach; J Blatter; U Ohnmacht; A- R Hanauske
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.